Some PARP-1 and PARP-2 inhibitors, such as olaparib, niraparib, rucaparib, veliparib, and talazoparib, which are small-molecule NAD+ mimetics, are currently being studied in later-stage clinical trials or are already approved for breast and ovarian cancer treatment with deleterious germline BRCA1 and BRCA2 mutations, which predispose women to develop triple-negative and hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancers, respectively [34,35]. This evidence concerns the gene BRCA2 and ovarian carcinoma.